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Background: The purpose of this study is to evaluate the prevalence, antimicrobial susceptibilities, and visual acuity
outcome of acute-onset postoperative Gram-negative bacterial endophthalmitis cases resistant to both ceftazidime
and amikacin seen between 2005 and 2010 at L. V. Prasad Eye Institute, a tertiary care ophthalmic Centre in South
India. Medical records of all patients with Gram-negative bacterial endophthalmitis resistant to both amikacin and
ceftazidime between 1 January 2005 and 31 December 2010 were reviewed in this non-comparative, consecutive,
retrospective case series. Favorable outcome was defined as a best-corrected visual acuity of ≥20/200.
Results: Sixty five (39.6%) of 164 culture-positive postoperative endophthalmitis were caused by Gram-negative
organisms. Among these 65 isolates, 32 (49%; 95% confidence interval (CI) 37% to 61%) were resistant to
ceftazidime, 17 (26%; 95% CI 15% to 37%) to amikacin, and 12 (18.5%; 95% CI 9% to 27%) to both ceftazidime and
amikacin. Eight Pseudomonas isolates, three Enterobacter isolates, and one Haemophilus isolate were resistant to
both ceftazidime and amikacin. The isolates were sensitive to fluoroquinolones (42%) and imipenem (50%).
Presenting visual acuity was light perception in 10 (83.3%) cases. A final visual acuity ≥20/200 was achieved in 5/12
(41.7%) of these patients.
Conclusion: In the current study, Pseudomonas was the most common Gram-negative bacteria resistant to both
amikacin and ceftazidime. The emergence of multidrug-resistant bacteria causing endophthalmitis is a matter of
concern in India. Alternative antibiotics like imipenem or fluoroquinolones may be considered for the management
of these resistant organisms.
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Gram-negative bacteria are less common cause of acute-
onset endophthalmitis following cataract surgery [1].
Gram-negative organisms have been isolated in 26% to
42% of patients with cataract surgery related to endoph-
thalmitis in developing countries [1-3] as compared to
5.9% to 12.2% in developed countries [4-12]. The com-
mon Gram-negative organisms causing endophthalmitis
include species of Pseudomonas, Haemophilus, Klebsiella,
and Proteus. Intravitreal ceftazidime or amikacin are com-
monly used for the empiric treatment of Gram-negative
organisms in endophthalmitis. In the Endophthalmitis
Vitrectomy Study (EVS), 11% of Gram-negative bacteria
were resistant to both amikacin and ceftazidime [5]. The
sensitivity of Gram-negative isolates reported from India
is 61% to 63% to ceftazidime, 68% to 82% to amikacin, and
73% to 87% to ciprofloxacin [1,2]. Three decades ago
(1980 to 1990), the sensitivity of Gram-negative isolates
was 98% to amikacin and 100% to ceftazidime [13].
In the current study, the prevalence, antimicrobial sus-
ceptibilities, and visual acuity outcome of patients with
acute-onset postoperative endophthalmitis is reported
for Gram-negative bacteria which were resistant to both
ceftazidime and amikacin.
Methods
Approval was obtained from the local institutional re-
view board and the study followed the Declaration of
Helsinki guidelines. Patients with acute-onset postoper-
ative endophthalmitis caused by Gram-negative bacteria
occurring between January 2005 and December 2010
and antimicrobial sensitivity data were obtained from
the microbiology database. Of these, the isolates resist-
ant to both ceftazidime and amikacin were included in
the study and clinical records of these patients were
reviewed and analyzed.
All patients were managed by the standard institutional
protocol for management of acute endophthalmitis [14].
This essentially consisted of vitreous biopsy or vitrectomy,
microscopy, and culture sensitivity of undiluted vitreous,
intravitreal antibiotics (vancomycin (1 mg/0.01 ml) + ami-
kacin (400 μg/0.01 ml)/ceftazidime (2.25 mg/0.01 ml)) with
or without dexamethasone (400 μg/0.01 ml). Intensive top-
ical antibiotics (ciprofloxacin 0.3% half hourly) and cortico-
steroid (prednisolone acetate 1%) were administered in all
patients. Additional procedures such as repeat intravitreal
antibiotics or pars plana vitrectomy/vitreous lavage were
performed by the individual treating physicians without a
predefined study protocol. Bacterial isolates were identified
using Analytical Profile Index (API, Bio Meriux, Craponne,
France). The antibiotic sensitivity was checked by the Kirby
Bauer disc diffusion method. Anatomical success was de-
fined as the intraocular pressure ≥10 mmHg and best cor-
rected visual acuity ≥20/200.Results and discussion
Results
A total of 510 acute-onset postoperative endophthalmitis
patients were identified between 2005 and 2010. Sixty
five (39.6%; 95% confidence interval (CI) 32.1% to 47.1%)
of 164 culture-positive postoperative endophthalmitis were
caused by Gram-negative organisms. Among the 65 Gram-
negative cases, 32 (49%; 95% CI 37% to 61%) cases were re-
sistant to ceftazidime, 17 (26%; 95% CI 15% to 37%) were
resistant to amikacin, and 12 (18%; 95% CI 9% to 27%)
were resistant to both ceftazidime and amikacin.
The mean age of these 12 patients was 61.67 years,
ranging from 40 to 85 years. Median time from cataract
surgery to onset of symptoms was 7.5 days (range 1 to
14 days). Ten of 12 patients presented with visual acuity
of light perception, one had 20/600 and the other 20/80
(Table 1). Ten of 12 patients had hypopyon at presenta-
tion and optic disc was visible on indirect ophthalmos-
copy in 3 of 12 patients.
The combined ceftazidime and amikacin resistance
was commonly noted in Pseudomonas aeruginosa (8/38,
21.05%) followed by Enterobacter (3/5, 60%) and
Haemophilus (1/3, 33.3%) (Table 1). Out of these 12
isolates, five were susceptible to all fluoroquinolones and
six were susceptible to imipenem (Table 2). In total, 11 of
12 isolates were susceptible to either of these two drugs.
One Pseudomonas isolate was resistant to all the tested
antimicrobials (Table 2).
A visual acuity ≥20/200 at last follow-up was achieved
in five (41.7%) patients. Of the remaining seven patients
with visual acuity <20/200, six went into phthisis and
one eye developed thick epiretinal membrane with trac-
tion macular detachment. The patient with endophthal-
mitis caused by Haemophilus had a final visual acuity of
hand motions despite presenting with visual acuity of
20/80. In six (50%) patients the IOL was explanted,
which included four explantations during the primary
surgery and in two patients during additional interven-
tions. Nine patients required additional procedures such
as repeat intravitreal antibiotic injection with or without
vitrectomy (Table 1).
Discussion
The microbiological spectrum of acute-onset postopera-
tive endophthalmitis from different parts of the world
varies significantly. Staphylococcus sp. is the most com-
mon cause of acute-onset postoperative endophthalmitis
following cataract surgery [6-8]. Series from Australia
[9,10], North America [6], and Europe [11,12] have re-
ported 6% to 12% Gram-negative bacteria and in the
EVS reporting Gram-negative bacteria was isolated in
5.9% (19/323) eyes [5]. The Indian studies, at 26% to 42%,
have reported higher incidences of Gram-negative bacter-
ial infection [1,2]. Similarly, in a report from Turkey, a
Table 1 Microbial organisms, interventions, and visual outcome






















11 20/600 PPV + IOA 6 C + IOLex Yes 12 20/100
2 OD Pseudomonas
aeruginosa
9 LP PPV + IOA 1 None No 8 20/100
3 OD Enterobacter 11 LP PPV + IOA + IOLex 1 None Yes 1 LP
4 OS Enterobacter 2 LP PPV + IOA + IOLex 2 Imip Yes 16 20/40
5 OD Pseudomonas
aeruginosa
5 LP PPV + IOA + IOLex 2 Imip Yes 12 20/100
6 OS Haemophilus 1 20/80 PPV + IOA 2 Chlor No 1 HM+
7 OS Pseudomonas
aeruginosa
14 LP PPV + IOA 2 PPV No 8 HM+
8 OD Enterobacter 5 LP PPV + IOA 1 None No 8 LP
9 OS Pseudomonas
aeruginosa
14 LP PPV + IOA + IOLex 2 C + D Yes 1 LP
10 OD Pseudomonas
aeruginosa
7 LP PPV + IOA 9 Imip + IOLex Yes 12 HM+
11 OD Pseudomonas
aeruginosa
8 LP PPV + IOA 2 C + D No 2 LP
12 OD Pseudomonas
aeruginosa
10 LP PPV + IOA 4 Imip + D No 16 20/120
In patients with acute postoperative Gram-negative endophthalmitis resistant to both ceftazidime and amikacin. PPV, pars plana vitrectomy; IOA intraocular
antibiotic; Imip, imipenem; C, ciprofloxacin; D, dexamathasone; Chlor, chloremphenicol; IOLex, intraocular lens explantation; LP, light perception; HM, hand motion;
BCVA, best-corrected visual acuity.
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35.1% of cases [3].
Current empirical therapies for endophthalmitis gener-
ally include vancomycin (1.0 mg/0.1 ml) and ceftazidime
(2.25 mg/0.1 ml) or amikacin (0.4 mg/0.1 ml). EVS re-
ported the sensitivity rate of 89.5% for both amikacinTable 2 Antibiotic susceptibility in patients with acute postop
ceftazidime and amikacin
No. Organism A Cefa Cefta Chlor
1 Pseudomonas aeruginosa R R R R
2 Pseudomonas aeruginosa R R R R
3 Enterobacter R R R R
4 Enterobacter R R R R
5 Pseudomonas aeruginosa R R R R
6 Haemophilus R - R S
7 Pseudomonas aeruginosa R - R R
8 Enterobacter R - R R
9 Pseudomonas aeruginosa R - R R
10 Pseudomonas aeruginosa R - R R
11 Pseudomonas aeruginosa R R R R
12 Pseudomonas aeruginosa R R R R
A, amikacin; Cefa, cefazolin; Cefta, ceftazidime; Chlor, chloramphenicol; Genta, gent
Pipera, piperacillin; Ticar, ticarcillin; S, sensitive; R, resistant.and ceftazidime among Gram-negative isolates [5]. An-
other study from the USA has shown the sensitivity of
Gram-negative bacteria to ceftazidime and amikacin at
99% and 100%, respectively [15]. In India, susceptibility of
Gram-negative bacteria to amikacin (68% to 82%) and cef-
tazidime (61% to 63%) is much lower [1,2]. We speculateerative, Gram-negative endophthalmitis resistant to both
Genta Cipro Gati Imip Oflox Pipera Ticar
R S S R S - -
R S S R S R R
R R R S R R R
R R R S R R R
R R R S R R R
R S S R S - -
R R R R R R R
R R R S R R R
R S S R S - -
R R R S R R R
R S S R S - -
R R R S R R R
amicin; Cipro, ciprofloxacin; Gati, gatifloxacin; Imip, imipenum; Oflox, ofloxacin;
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of multidrug resistance among Gram-negative organisms
as a probable cause [16,17].
There may be several mechanisms that contribute to the
development of aminoglycoside resistance. These include
the deactivation of aminoglycosides by aminoglycoside-
modifying enzymes. Other mechanisms include the reduc-
tion of the intracellular concentration of aminoglycosides
by changes in the outer membrane permeability which is
usually a non-specific resistance mechanism, inner mem-
brane transport, active efflux or drug trapping, the alter-
ation of the 30S ribosomal subunit target by mutation,
and finally methylation of the aminoglycoside-binding site
[18]. Efflux pumps and inhibition of drug intake are com-
mon components of multidrug-resistant Pseudomonas
isolates which prevent accumulation of antibacterial drugs
within the bacterium [19].
Ceftazidime is a third-generation cephalosporin and
belongs to the beta lactam class of antibiotics. The most
common mechanism of resistance to beta lactam antibi-
otics is by enzymatic deactivation of the drug. Beta lac-
tamase produced by various Gram-negative bacteria
renders them inherently resistant to most of the beta
lactam antibiotics except third- and fourth-generation
cephalosporins. Pseudomonas has an additional capabil-
ity of producing AmpC β-lactamase (also known as
cephalosporinase) whose activity is not inhibited by β-
lactamase inhibitors including clavulanic acid, sulbac-
tam, and tazobactam [20].
Among the fluoroquinolones, ciprofloxacin is generally
the most effective drug against Pseudomonas. Other bac-
teria like Salmonella, Shigella, Neisseria, and Haemophi-
lus are highly susceptible to ciprofloxacin regardless of
whether the organisms produce β-lactamase or not [21].
The susceptibility profile of ciprofloxacin is reportedly
superior to ceftazidime for Gram-negative organisms
[1,2,22]. Resistance to fluoroquinolones in general and
to ciprofloxacin in particular is reportedly low [23-25].
Also, in our study, ciprofloxacin was the drug of choice
against Gram-negative bacteria [26]. In our database, out
of the 65 cases of Gram-negative bacterial postoperative
endophthalmitis, 77% isolates were sensitive to cipro-
floxacin, and in the current series, nearly 42% of Gram-
negative bacteria that were resistant to both ceftazidime
and amikacin showed susceptibility to ciprofloxacin. Since
the elimination half-life of intravitreal ciprofloxacin is short
[27], oral administration may be considered in such pa-
tients. The intravitreal concentration of ciprofloxacin after
oral administration has been demonstrated to be above the
minimum inhibitory concentration (MIC-90, i.e., minimum
antibiotic concentration inhibiting 90% of strains) of most
of the organisms in inflamed eyes [28].
In the current study, 50% of the Gram-negative isolates
which were resistant to both amikacin and ceftazidime weresensitive to imipenem. Imipenem has a broad spectrum
of activity against both aerobic and anaerobic and Gram-
positive and Gram-negative bacteria including Pseudo-
monas and Enterococcus species. It acts by inhibiting cell
wall synthesis of various Gram-positive and Gram-negative
bacteria [29]. It is stable to hydrolysis by the common
plasmid-mediated beta-lactamases produced by various
bacteria and lacks cross resistance with penicillins and
third-generation cephalosporins [30]. Intravitreal imipenem
may limit intraocular inflammation and retinal tissue
damage when given early in the course of Pseudomonas
endophthalmitis [31]. It is generally nontoxic in animal
models at concentrations that are far higher than the MIC
90 of 3.6 to 12.5 μg/ml against Pseudomonas infection and
may offer promise in the treatment of endophthalmitis after
intraocular surgery or perforating eye injuries [32].
In the EVS, 56% of eyes infected with Gram-negative
bacteria regained 20/100 [4]. Multidrug resistance is
more common in Gram-negative bacteria (78.6%) com-
pared to Gram-positive bacteria (21.4%) [33]. The multi-
drug resistance and higher number of Pseudomonas in
the current study may explain the poorer outcome in
this study as compared to EVS.
There are certain limitations in this retrospective
study. Firstly, antibiotic susceptibility in this study was
tested by disc diffusion method and was not confirmed
by MIC. Secondly, the number of cases included in the
study is relatively small.
Conclusions
In conclusion, resistance to both amikacin and ceftazi-
dime among Gram-negative isolates was not uncommon
in the current study. Pseudomonas was the most com-
mon multidrug-resistant Gram-negative bacteria isolated
and the visual acuity outcomes were generally poor. An
alternative group of drugs like ciprofloxacin or imipe-
nem may be considered for the management of these
cases. Drug resistance is an emerging problem among
Gram-negative isolates causing acute-onset postopera-
tive endophthalmitis in India.
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